A game between two high-powered offenses ended up being a pitching duel as Paul Skenes and the USA edged the Dominican Republic to reach the World Baseball Classic title game.
From top prospects to spring surprises to veterans with something to prove, here is one player in each camp who has turned some heads during Spring Training.
Italy manager Francisco Cervelli finds himself in an interesting spot in the World Baseball Classic semifinal against Venezuela. He was born and raised in Venezuela after his Italian father immigrated there.
After Rays righty Shane McClanahan joked with Brandon Lowe before the game that he would hit him with a pitch, he found a different way to torment his former teammate.
MLB Network is live from Miami before and after tonight’s WBC semifinal game. Join Greg Amsinger, Harold Reynolds, Dan Plesac and Chris Young for highlights, interviews, news and more. Coverage begins at 6 p.m. ET.
Trouble viewing email? Click here You are subscribed to this newsletter as: peterhovis@icloud.com
BUY TICKETSMORE INFOMORE PROMOTIONSSingle game tickets for the D-backs regular season are on sale now! Don’t miss the biggest matchups and giveaways of the season. Get your tickets now at dbacks.com!
The epic semifinal between the United States and the Dominican Republic was everything it was hyped up to be.
Between both countries, including hitters and pitchers, there were 17 players who have already been All-Stars — the most All-Stars starting in a World Baseball Classic semifinal or final, surpassing the 11 who played in the 2017 WBC final between the USA and Puerto Rico.
It was quite possibly the most talent on a baseball field in a single game with stakes, ever.
Love New Times? Thanks to a recent Google update, you can now select us as a preferred source to see our stories first in search results. Thank you in advance for your ongoing support of local journalism.
Jesus Christ, my God, I adore You and thank You for all the graces You have given me this day. I offer You my sleep and all the moments of this night. I place myself and all my loved ones, wherever they may be, in Your sacred side and under the mantle of Our Blessed Mother. Let Your holy angels stand watch and keep us in peace. Amen.
Quote of the Day
“And when the centurion, who stood facing him, saw that he thus breathed his last, he said, ‘Truly this man was the Son of God!’” -Mark 15:39
Today’s Meditation
Then, before my eyes, I saw my beloved Child raised up on the cross and fixed to its hard wood with piercing and unrelenting nails. All the while, He remained like a gentle lamb in the presence of its shearers, not uttering a word nor opening His mouth. Thus I, the handmaid of the Lord, looked upon my Master being tortured! Thus I, the Mother of God, saw my Son hanging from the cross, dying in the throngs of a shameful and ignominious death. The pain and agony which tore through my heart ehn was so intense that no words could ever express it. His blood gushed forth from the four wounds He then bore — upon each of His hands and feet, where the nails had penetrated His holy flesh. As a crimson flood, His precious blood poured onto the wood of the cross and covered the iron of the nails. —Mary to St. Bernard
Make Easter Cuvée the centerpiece of your celebration, a beautifully crafted sparkling wine created for moments of renewal, joy, and gathering around the table. Elegant, vibrant, and festive, it’s the perfect way to toast the season of hope.
Discover more from Trinitas Cellars’ faith-inspired collection, including the Pope Leo Wine and the Marian Series, each bottle reflecting devotion, tradition, and purpose.
Share the gift of wine this Easter and enjoy 20% off your first order with code TRINITY at TrinitasCellars.com.
The daily examination of conscience is an ancient Catholic practice. It’s very simple, and it’s designed to help us identify our sins and weaknesses so that we can improve and grow stronger in the spiritual life, while providing an excellent ongoing preparation for regular Confession. It consists of taking a few minutes at the end of the day to prayerfully review our actions in the light of God’s commandments, followed by the Act of Contrition.
Reflect on the victories and losses
Actively reflecting on the high and low points of the day can help you live more intentionally and bring a renewed sense of resolve into the following day.
Review your actions, words, and thoughts today. Did you actively guard yourself against temptation? Where did sin creep in?
In what moments did you practice virtue and moral courage?
Were you attuned to the Holy Spirit’s promptings today? Where did you feel His inspiration?
Ask Him for the graces necessary to follow His Will more purposefully tomorrow.
Act of Contrition
O my God, I am heartily sorry for having offended Thee, and I detest all my sins because of Thy just punishments, but most of all because they offend Thee, my God, Who art all good and deserving of all my love. I firmly resolve with the help of Thy grace to sin no more and to avoid the near occasions of sin. Amen.
Practice gratitude
It is God’s love that has brought you into existence and to this exact moment. Practice looking for His hand in your day.
Where did you feel His loving gaze upon you today?
What people or moments helped you see God in your life?
Thank God for all these moments!
Ask Him to help you recognize His blessings and providence tomorrow.
Renew your commitment to Christ
Remember: our Faith is founded upon a Person—Christ! Renew your personal love and devotion to Him.
Thank God for the gift of His Son Jesus and our call to be His disciples.
Tell the Lord of your desire to know Christ more personally.
If possible, set an intention for your day tomorrow. Ask Our Lord to guide you in this act.
Pray a Hail Mary, Our Father, or another beloved prayer.
Rest with God
In peace I will both lie down and sleep; for Thou alone, O Lord, makest me dwell in safety. — Psalm 4:8
Patience Pays: Hims & Hers Surges on News of Novo Nordisk Deal
Written by Jordan Chussler on March 10, 2026
Key Points
Hims & Hers has shifted from offering controversial compounded GLP-1s to a formal agreement with Novo Nordisk, allowing the platform to distribute FDA-approved Ozempic and Wegovy.
Following the announcement, HIMS shares surged nearly 46%, helping the stock recover from a 59% drop earlier in the year caused by previous legal friction with Novo Nordisk.
Analysts have upgraded the stock, citing the partnership as a major growth catalyst; despite a year-to-date loss, earnings are projected to grow by over 79% next year.
After falling 59% from its year-to-date (YTD) high, embattled healthcare stock Hims & Hers Health (NYSE: HIMS) is making headlines as shares are surging in the wake of an agreement with GLP-1 maker Novo Nordisk (NYSE: NVO)—the very company that filed a patent infringement lawsuit against Hims & Hers on Feb. 9.
After having to pull its compounded semaglutide modeled after Novo Nordisk’s weight loss drugs, Wegovy and Ozempic, Hims & Hers announced in a press releasethat the two firms have entered into a strategic partnership, making Novo Nordisk’s obesity drugs available through the telehealth platform.
Since the announcement, HIMS has gained nearly 46% along with analyst upgrades as Wall Street turns bullish on the direct-to-consumer prescription drug provider.
Weiss expert Chris Graebe just revealed a unique gold-related investment that offers much higher upside than gold itself without the downside price risk—private, pre-IPO shares insulated from daily market volatility in a company that has pioneered a new way to extract and process gold 10 times faster and up to 70 times cheaper than a traditional miner without owning or operating a single mine. This is a rare chance to invest in the Alpha Round of funding, one of the earliest and most rewarding pre-IPO funding rounds, with examples of Alpha Round deals that delivered returns as high as 552,332%, enough to grow a $1,000 stake into $5.5 million.Watch the Private Investment Summit for all the facts now
A Strategic Shift From Compounded GLP-1 to FDA-Approved Drugs
Amid surging demand and subsequent shortages for weight loss drugs, compounded GLP-1 alternatives emerged to fill the void. However, compounded GLP-1 drugs lack U.S. Food and Drug Administration (FDA) approval.
While they increased affordable access to substitutes for brand-name drugs like Ozempic and Wegovy, while offering similar ingredient profiles (e.g., semaglutide and tirzepatide, the latter of which is marketed as Mounjaro and Zepbound), the absence of FDA approval means that those alternative drugs lacked quality and efficacy reviews, thereby posing a risk of incorrect dosages, improper storage, and other safety issues.
According to Hims & Hers’s press release, as a part of the company’s shift away from compounded GLP-1 offerings, “existing patients will have the opportunity to transition to FDA-approved medicines.”
Specifically, “Hims & Hers has entered into an agreement with Novo Nordisk that will bring Ozempic (semaglutide) 0.5 mg, 1 mg, and 2 mg injections and Wegovy (semaglutide) pills and injections to the platform later this month, including 1.7 mg or 2.4 mg injections and 1.5 mg, 4 mg, 9 mg, and 25 mg tablets.”
Co-founder and CEO Andrew Dudum noted that the deal should result in “tremendous growth opportunities in the U.S. with the expanding assortment of branded GLP-1 medications.” Dudum added that the “collaboration reflects what’s possible globally when drugmakers, biotech companies, and diagnostic leaders partner with consumer platforms to support scaled distribution of their latest medical innovations.”
Shares of HIMS Are Still Struggling, But the Future Looks Promising
The recent news, as well as the sizable bump in the stock’s price, was warmly welcomed by shareholders who have dealt with Hims & Hers’ volatility over the past year. Even in the wake of the Novo Nordisk-induced sell-off in February, analysts remained bullish on the stock, with some 12-month price targets implying as much as 150% potential upside.
Even with the March 9 surge, HIMS shares are still down nearly 33% over the last 12 months. But fundamentally, Hims & Hers looks well-positioned to sustain its run.
When the company reported full-year and Q4 2025 earnings on Feb. 23, it announced an earnings per share (EPS) beat and a revenue miss. EPS of 8 cents surpassed analyst expectations of 2 cents, while revenue of $617.82 million fell short of expectations of $619.48 million.
It was the company’s first EPS beat since the first quarter of last year. But just as importantly, the financial metrics showed steady, sustainable revenue growth, with a three-year average of 64.60%. And while earnings contracted in 2025, that followed EPS growth of nearly 582% in 2024 and nearly 66% in 2023.
Hims & Hers Health’s earnings are expected to grow 79.31% next year, from 29 cents per share to 52 cents per share.
Tesla built its name on electric cars, but earlier this year, Elon signaled something that caught my attention—production on certain vehicle models would be scaled back to make room for something else: robots. Wall Street doesn’t always price transitions like these correctly at first, and for traders, that tension is where opportunity lives—I’ve already revealed how this cars-to-robots shift could influence Tesla’s price action over the next few months plus the levels I’m watching if volatility expands.See the entire Tesla setup right here now
HIMS Receives Analyst Upgrades as Wall Street Turns Bullish on Telehealth
Following the announcement of the Novo Nordisk deal, Bank of America Securities upgraded HIMS stock to Neutral from Underperform and raised its price target to $23 from $12.50.
Notably, the firm’s previous price target excluded contributions from GLP-1 revenue, showing that the agreement with Novo Nordisk is being seen as an extremely bullish catalyst on Wall Street.
Overall, the stock receives a consensus Hold rating based on 17 analysts currently covering the stock. The average one-year price target implies more than 32% potential upside.
Current short interest of 43.24% of the shares outstanding should be monitored, but that figure—which equates to $1.32 billion worth of shares—is substantially lower than the $4.27 billion that were shorted last July. That downtrend has steadily continued, and it would not be surprising if institutional buyers once again outnumber sellers in the quarters ahead as the deal with Novo Nordisk will bolster Hims & Hers’ top-line growth.
Thank you for subscribing to DividendStocks.com’s daily newsletter for dividend and income investors that covers ex-dividend stocks, new dividend declarations, dividend stock ideas, and the latest market news.
If you have questions about your account, please contact MarketBeat’s South Dakota based support team at contact@marketbeat.com.
If you no longer wish to receive email from DividendStocks.com, you can unsubscribe.
RJ Hamster 